Dobutamine

What dobutamine is and how it works

Dobutamine is an intravenous medicine that helps the heart pump more effectively (a positive inotrope). It is given only in a hospital or acute-care setting, always under continuous heart monitoring, for short-term treatment of cardiac decompensation (reduced heart pumping strength) following conditions such as a heart attack, cardiac surgery, cardiomyopathy, or septic/cardiogenic shock. It is also used, in a controlled diagnostic setting, as part of a dobutamine stress echocardiogram to help detect reduced blood flow to the heart. (1) (2)

Dobutamine does not carry a boxed warning in any of the markets reviewed for this page, but it does have a real, well-documented risk: it can cause the heart to beat abnormally fast or irregularly (proarrhythmic/tachyarrhythmic effects), and can raise heart rate and blood pressure. This is why it is only ever given in a monitored hospital or diagnostic-testing setting with continuous heart-rhythm (ECG) and blood-pressure tracing -- it is never a medicine you take yourself at home.

Mechanism of action: how dobutamine works

Dobutamine is a synthetic catecholamine and direct-acting inotropic agent whose primary activity results from stimulation of cardiac beta-1 receptors, producing comparatively mild chronotropic (heart-rate), hypertensive, arrhythmogenic, and vasodilatory effects relative to its inotropic (contractility) effect. It is rapidly metabolised, primarily via catechol-O-methyltransferase, with an elimination half-life of approximately 2 minutes. (1) (2)

What dobutamine is used for

Before taking dobutamine

Do not take / not appropriate for

• Must not be given to anyone with a known hypersensitivity (allergic reaction) to dobutamine. (all countries) (1) (2)
• Must not be given to patients with idiopathic hypertrophic subaortic stenosis, a heart condition where dobutamine's effect on the heart's pumping action can worsen the obstruction. (United States) (1)
• Must not be given to patients with mechanical obstruction to ventricular filling or outflow (e.g. cardiac tamponade, constrictive pericarditis, severe aortic stenosis), hypovolaemia (low blood volume, which must be corrected first), or phaeochromocytoma (an adrenaline-producing adrenal tumour). (United Kingdom, European Union) (2)
• For the stress-echocardiography use specifically: not used within 30 days of a heart attack, with unstable angina, significant arrhythmias, or poorly controlled high blood pressure. (United Kingdom, European Union) (2)

Tell your clinician about

• This section is intended for the clinical team managing an inpatient, monitored infusion or supervised stress test, not for patient self-management -- dobutamine is never self-administered.
• Any history of abnormal heart rhythms (arrhythmias), including atrial fibrillation.
• Any history of angina, recent heart attack, or coronary artery disease.
• Whether the patient takes a beta-blocker medicine, since this can blunt dobutamine's effect.
• Whether the patient has low blood volume (hypovolaemia), which should be corrected before starting.
• Any history of a phaeochromocytoma (adrenal tumour).

How to take dobutamine

• Given only by intravenous infusion, after dilution, in a hospital or closely monitored acute-care/diagnostic-testing setting -- never self-administered.
• Continuous ECG (heart rhythm) and blood pressure monitoring are required throughout the infusion; pulmonary wedge pressure and cardiac output are monitored whenever possible.
• For diagnostic stress testing, the infusion rate is increased stepwise (e.g. 5, then 10, 20, 30, and a maximum of 40 micrograms/kg/minute, each step over about 3 minutes) in a unit equipped with a defibrillator and resuscitation-trained staff.

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

Not applicable in the usual sense -- dobutamine is given as a continuous, clinician-managed hospital infusion or a single supervised diagnostic-test infusion, so a 'missed dose' is a clinical monitoring matter for the care team, not something a patient manages.

Overdose

Because dobutamine is administered and continuously monitored by a healthcare team, any concern about an excessive rate is identified and managed directly by that team, typically by reducing or stopping the infusion. Toxicity symptoms may include loss of appetite, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and chest pain; higher exposure may cause high blood pressure, fast/irregular heart rhythms, reduced blood flow to the heart, or, rarely, dangerous ventricular fibrillation, all managed supportively by the treating team. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Serious warnings

Interactions

• Beta-blocker medicines: compete with dobutamine at the same receptors, reducing its intended effect; unopposed alpha-receptor effects may instead raise blood pressure. (2)
• Inhaled anaesthetics: increase heart-muscle excitability and the risk of ventricular arrhythmia when combined with dobutamine -- used with caution together. (2)
• ACE inhibitors: at high doses in combination, cardiac output rises alongside the heart muscle's oxygen consumption. (2)
• Dopamine: combined use produces a more pronounced rise in blood pressure than either medicine alone. (2)
• Entacapone: may potentiate (increase) dobutamine's effects. (2)

Pregnancy, breastfeeding, kidney/liver function, age

Monitoring

Before starting

• Baseline ECG and cardiac rhythm assessment
• Baseline blood pressure and heart rate
• Correction of hypovolaemia before starting, where present
• Baseline serum potassium

During treatment

• Continuous ECG monitoring throughout the infusion, in a setting equipped for immediate management of arrhythmias.
• Continuous blood pressure monitoring, with infusion-rate reduction if excessive increases develop.
• Pulmonary wedge pressure and cardiac output monitoring whenever possible.
• Serum potassium monitoring, since dobutamine can cause a mild reduction.
• For stress echocardiography: continuous monitoring in a unit with a defibrillator and resuscitation-trained personnel available throughout.

Storage

Stored and prepared by hospital pharmacy/clinical staff according to the product's specific storage and dilution requirements; not self-stored by patients at home.

Frequently asked questions

References

1. DOBUTAMINE injection, USP -- full prescribing informationDailyMed / Pfizer official prescribing information (FDA-approved drug labeling) · United States · accessed 2026-07-31 · source 1
2. Dobutamine 5 mg/ml solution for infusion -- Summary of Product Characteristics (SmPC)electronic medicines compendium (emc), United Kingdom -- hameln pharma ltd · United Kingdom · accessed 2026-07-31 · source 2
3. Dobutamine 12.5 mg/ml Concentrate for solution for infusion -- HPRA Ireland licence PA2299-039-001Health Products Regulatory Authority (HPRA), Ireland -- national marketing authorisation · European Union (Ireland, as a directly confirmed EU member state) · accessed 2026-07-31 · source 3
4. Dobutamine Injection USP (as Dobutamine Hydrochloride) -- Health Canada Product Monograph, Pfizer Canada ULCHealth Canada -- Product Monograph · Canada · accessed 2026-07-31 · source 4
5. DOBUTAMINE-AFT, DBL DOBUTAMINE, DOBUTREX, and Hospira Dobutamine Hydrochloride Injection -- multiple current ARTG entriesTherapeutic Goods Administration (TGA), Australia -- Australian Register of Therapeutic Goods (ARTG) · Australia · accessed 2026-07-31 · source 5
6. Dobutamine-hameln 12.5 mg/ml concentrate for solution for infusion; DBL-brand dobutamine hydrochloride injection -- New Zealand Data SheetsMedsafe (New Zealand regulator) -- New Zealand Data Sheet · New Zealand · accessed 2026-07-31 · source 6

Brand names by country

Single-ingredient dobutamine names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries